Pathak Holdings, LLC

United States of America

Back to Profile

1-19 of 19 for Pathak Holdings, LLC Sort by
Query
Aggregations
Jurisdiction
        United States 15
        World 4
Date
2025 June 1
2025 (YTD) 1
2024 3
2022 1
2021 2
See more
IPC Class
A61K 9/00 - Medicinal preparations characterised by special physical form 13
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin 13
A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges 13
A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2) 12
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol 12
See more
Status
Pending 4
Registered / In Force 15
Found results for  patents

1.

FLEXIBLE INTERCONNECTED MICROPARTICLES ARRAYS: DEVICES, METHODS, COMPOSITIONS AND APPLICATIONS

      
Application Number 19056429
Status Pending
Filing Date 2025-02-18
First Publication Date 2025-06-12
Owner Pathak Holdings LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

This invention pertains to an advanced implantable surgical array system, wherein array elements, composed of hydrogels or organogels, are intricately connected by a flexible thread. These elements are uniquely embedded within the device through a novel method that involves casting the hydrogel or organogel directly around the thread from a liquid/fluid precursor solution, which upon drying or cross-linking, integrates the thread into the array elements without the necessity for traditional threading techniques. The disclosed arrays are versatile, capable of being configured into various structural forms including single particle arrays, chain-like arrays, as well as two-dimensional and three-dimensional matrices. This innovative approach not only facilitates controlled drug delivery over extended periods but also incorporates features to prevent element migration and enables the device to assume expanded or compressed configurations for ease of implantation.

IPC Classes  ?

  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/06 - OintmentsBases therefor
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/50 - Microcapsules
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 31/727 - HeparinHeparan
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 47/02 - Inorganic compounds
  • A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61L 27/38 - Animal cells
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges
  • A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

2.

CROSSLINKED MULTILAYERED MATERIAL COMPOSITIONS, METHODS FOR THEIR PREPARATION AND APPLICATIONS THEREOF

      
Application Number 18797043
Status Pending
Filing Date 2024-08-07
First Publication Date 2024-12-05
Owner Pathak Holdings LLC (USA)
Inventor
  • Pathak, Chandrashekhar P.
  • Thigle, Milind

Abstract

Novel composite materials and their methods of preparation comprising a crosslinked biodegradable polymer and non-crosslinked biodegradable polymers are disclosed. The composite materials can be formed into injectable compositions comprising composite microparticles or microspheres. The non-crosslinked biodegradable polymer in the composite material is synthesized or precipitated in situ inside the particle. The non-crosslinked biodegradable polymer in the composite may be liquid, low melting solid or polymer with thermosensitive or pH sensitive gelation properties. Also disclosed are injectable compositions comprising microparticles or microspheres for controlled drug delivery wherein such particles are delivered using organic solvents. Also disclosed are methods and compositions for making two or more layered particles for medical and industrial use.

IPC Classes  ?

  • B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • C08F 2/50 - Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light with sensitising agents

3.

METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYS

      
Application Number 18620289
Status Pending
Filing Date 2024-03-28
First Publication Date 2024-08-01
Owner Pathak Holdings LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

This invention discloses methods and composition to form biodegradable polymer implant arrays in the live tissue. Artificial cavities are created in the live tissue by using laser ablation, oscillating needle, microneedle array and other methods. The cavities are then filled with biodegradable polymer solution. The solvent in the polymer solution is dissipated in the tissue to form a biodegradable polymer implant in artificial cavities. The cavities and implants formed are arranged to form of an array of implants. The biodegradable polymer in the cavity can also be loaded with drug to form biodegradable drug delivery array in the live tissue.

IPC Classes  ?

  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/06 - OintmentsBases therefor
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/50 - Microcapsules
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 31/727 - HeparinHeparan
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 47/02 - Inorganic compounds
  • A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61L 27/38 - Animal cells
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

4.

PERSONAL CARE DEVICES AND COSMETIC COMPOSITIONS

      
Application Number US2023027795
Publication Number 2024/015589
Status In Force
Filing Date 2023-07-14
Publication Date 2024-01-18
Owner PATHAK HOLDINGS LLC (USA)
Inventor
  • Pathak, Chandrashekhar, P.
  • Thigle, Milind, Madhukar
  • Achalkar, Akshay, Santosh

Abstract

Novel disposable wet shaving razor designs with two or more cartridges with 3 or more blades are disclosed wherein the two cartridges are parallel to each other, are not connected with each other and distance between the cartridges is 0.1 mm to 5 cm. Also disclosed are wet shaving razor designs wherein the razor has two or more cartridges and ability to dispense cosmetic compositions stored in the razor handle. The invention also discloses cosmetic compositions based on organogels.

IPC Classes  ?

  • B26B 21/22 - Safety razors with one or more blades arranged transversely to the handle involving several blades to be used simultaneously
  • B26B 21/44 - Means integral with, or attached to, the razor for storing shaving-cream, styptic, or the like
  • B26B 19/38 - Details of, or accessories for, hair clippers or dry shavers, e.g. housings, casings, grips or guards
  • B26B 19/40 - Lubricating

5.

CROSSLINKED MULTILAYERED MATERIAL COMPOSITIONS, METHODS FOR THEIR PREPARATION AND APPLICATIONS THEREOF

      
Application Number 17503063
Status Pending
Filing Date 2021-10-15
First Publication Date 2022-04-21
Owner Pathak Holdings LLC (USA)
Inventor
  • Pathak, Chandrashekhar P.
  • Thigle, Milind M.

Abstract

Novel composite materials and their methods of preparation comprising a crosslinked biodegradable polymer and non-crosslinked biodegradable polymers are disclosed. The composite materials can be formed into injectable compositions comprising composite microparticles or microspheres. The non-crosslinked biodegradable polymer in the composite material is synthesized or precipitated in situ inside the particle. The non-crosslinked biodegradable polymer in the composite may be liquid, low melting solid or polymer with thermosensitive or pH sensitive gelation properties. Also disclosed are injectable compositions comprising microparticles or microspheres for controlled drug delivery wherein such particles are delivered using organic solvents. Also disclosed are methods and compositions for making two or more layered particles for medical and industrial use.

IPC Classes  ?

  • B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
  • C08F 2/50 - Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light with sensitising agents
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

6.

Methods, compositions, and devices for making sustained biodegradable implants in tissue

      
Application Number 17324738
Grant Number 11969398
Status In Force
Filing Date 2021-05-19
First Publication Date 2021-09-09
Grant Date 2024-04-30
Owner PATHAK HOLDINGS LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

This invention discloses methods and composition to form biodegradable polymer implant arrays in the live tissue. Artificial cavities are created in the live tissue by using laser ablation, oscillating needle, microneedle array and other methods. The cavities are then filled with biodegradable polymer solution. The solvent in the polymer solution is dissipated in the tissue to form a biodegradable polymer implant in artificial cavities. The cavities and implants formed are arranged to form of an array of implants. The biodegradable polymer in the cavity can also be loaded with drug to form biodegradable drug delivery array in the live tissue.

IPC Classes  ?

  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/06 - OintmentsBases therefor
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/50 - Microcapsules
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 31/727 - HeparinHeparan
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 47/02 - Inorganic compounds
  • A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61L 27/38 - Animal cells
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

7.

Compositions, methods and devices for forming implants from injected liquids

      
Application Number 17141656
Grant Number 11911352
Status In Force
Filing Date 2021-01-05
First Publication Date 2021-05-06
Grant Date 2024-02-27
Owner PATHAK HOLDINGS LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

A method of forming an implant in tissue can include: providing a polymer solution having an effective amount of polymer dissolved in a biocompatible, water-soluble organic solvent; injecting a plurality of droplets of the polymer solution in the tissue; fusing the injected droplets together; dissipating the biocompatible, water-soluble organic solvent in the tissue; and precipitating the polymer from the injected polymer solution so as to form the implant.

IPC Classes  ?

  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/727 - HeparinHeparan
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

8.

Method of making an in situ sustained biodegradable drug delivery implant by filling an artificial tissue cavity

      
Application Number 16818944
Grant Number 11045433
Status In Force
Filing Date 2020-03-13
First Publication Date 2020-07-23
Grant Date 2021-06-29
Owner Pathak Holdings LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

This invention discloses methods and composition to form biodegradable polymer implant arrays in the live tissue. Artificial cavities are created in the live tissue by using laser ablation, oscillating needle, microneedle array and other methods. The cavities are then filled with biodegradable polymer solution. The solvent in the polymer solution is dissipated in the tissue to form a biodegradable polymer implant in artificial cavities. The cavities and implants formed are arranged to form of an array of implants. The biodegradable polymer in the cavity can also be loaded with drug to form biodegradable drug delivery array in the live tissue.

IPC Classes  ?

  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61K 31/727 - HeparinHeparan
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61L 27/38 - Animal cells
  • A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
  • A61K 9/06 - OintmentsBases therefor
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61K 9/50 - Microcapsules
  • A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
  • A61K 47/02 - Inorganic compounds
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

9.

Methods for forming implants from injected thermoreversible gels

      
Application Number 16719642
Grant Number 10918611
Status In Force
Filing Date 2019-12-18
First Publication Date 2020-04-23
Grant Date 2021-02-16
Owner PATHAK HOLDINGS LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

A method of forming an implant in a tissue can include: providing an injectable liquid composition comprising one or more precursors of a crosslinkable composition; injecting the injectable composition into the tissue at the rate of about 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per injection; and crosslinking the one or more precursors of the crosslinkable composition so as to form a crosslinked composition.

IPC Classes  ?

  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/727 - HeparinHeparan
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

10.

Methods, compositions, and devices for drug/live cell microarrays

      
Application Number 16156949
Grant Number 10624865
Status In Force
Filing Date 2018-10-10
First Publication Date 2019-02-14
Grant Date 2020-04-21
Owner Pathak Holdings LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

Methods and compositions are for preparing microimplant arrays for sustained drug delivery or live cell based therapy. The “array in array” (AIA) device enables formation of microimplant arrays without having tissue piercing elements to the microimplant. The methods and compositions are for solid state delivery of drugs, especially biologics drugs without forming a drug solution prior to injection. New methods and compositions are for preparing in situ arrays for sustained drug delivery or live cell based therapy. Tissue surface is first treated with laser drilling, microneedle array, mechanical drilling or other methods to create artificial micro-porosity of various sizes, shapes and patterns. The artificial pores created are then infused with sustained drug delivery compositions or live cell suspensions. The compositions are converted into solid or semisolid state by physical or chemical reaction/s to entrap drug or live cells. The entrapped drug or live cells provide local or systemic therapeutic benefit.

IPC Classes  ?

  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61K 31/727 - HeparinHeparan
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61L 27/38 - Animal cells
  • A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
  • A61K 9/06 - OintmentsBases therefor
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61K 9/50 - Microcapsules
  • A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
  • A61K 47/02 - Inorganic compounds
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

11.

Compositions, methods and devices for forming gel implants from injected liquids

      
Application Number 16137332
Grant Number 10543182
Status In Force
Filing Date 2018-09-20
First Publication Date 2019-01-24
Grant Date 2020-01-28
Owner Pathak Holdings LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

2. The injecting can be at a depth of 10 microns to 5 mm. The injectable composition can include a visualization agent, drug or other agent.

IPC Classes  ?

  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/727 - HeparinHeparan
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

12.

METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYS

      
Application Number US2017042798
Publication Number 2018/017674
Status In Force
Filing Date 2017-07-19
Publication Date 2018-01-25
Owner PATHAK HOLDINGS, LLC (USA)
Inventor Pathak, Chandrashekhar, P.

Abstract

Methods and compositions are for preparing microimplant arrays for sustained drug delivery or live cell based therapy. The "array in array" (AIA) device enables formation of microimplant arrays without having tissue piercing elements to the microimplant. The methods and compositions are for solid state delivery of drugs, especially biologies drugs without forming a drug solution prior to injection. New methods and compositions are for preparing in situ arrays for sustained drug delivery or live cell based therapy. Tissue surface is first treated with laser drilling, microneedle array, mechanical drilling or other methods to create artificial micro-porosity of various size, shapes and patterns. The artificial pores created are then infused with sustained drug delivery compositions or live cell suspensions. The compositions are converted into solid or semisolid state by physical or chemical reaction/s to entrap drug or live cells. The entrapped drug or live cells provide local or systemic therapeutic benefit.

IPC Classes  ?

  • A61B 17/20 - Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges
  • A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
  • A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

13.

Compositions, methods and devices for forming implants from injected liquids

      
Application Number 15704792
Grant Number 10123980
Status In Force
Filing Date 2017-09-14
First Publication Date 2018-01-04
Grant Date 2018-11-13
Owner Pathak Holdings, LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

2. The neat liquid carrier can be injected at a depth of 10 microns to 5 mm. The neat liquid solution can include a drug or other agent.

IPC Classes  ?

  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/727 - HeparinHeparan
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

14.

Compositions, methods and devices for local drug delivery

      
Application Number 15099456
Grant Number 09789073
Status In Force
Filing Date 2016-04-14
First Publication Date 2016-08-25
Grant Date 2017-10-17
Owner Pathak Holdings, LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

This invention provide novel compositions, methods and devices for sustained drug delivery. The compositions can include a fluid carrier; a plurality of first polymeric microparticles having a bioactive agent dispersed in the fluid carrier; and a plurality of second polymeric microparticles having a visualization agent dispersed in the fluid carrier with the first microparticles. Alternative compositions can include: a fluid carrier; and a plurality of polymeric microparticles having a bioactive agent encapsulated therein and a visualization agent on a surface of the polymeric microparticles, the plurality of polymeric microparticles being dispersed in the fluid carrier. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes at an amount of 1.0E-03 mL to 1.0E-16 mL per injection.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/727 - HeparinHeparan
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

15.

Methods for local drug delivery by microinjection array

      
Application Number 14736007
Grant Number 09345777
Status In Force
Filing Date 2015-06-10
First Publication Date 2015-12-17
Grant Date 2016-05-24
Owner Pathak Holdings, LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

This invention provide novel compositions, methods and devices for sustained drug delivery. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes. The injected compositions may undergo variety of physical chemical changes upon deposition. The physical and chemical changes enables improved drug encapsulation and sustained drug release. Also described are new methods to form polymer microparticles or polymer films/implants in situ inside the tissue. The invention also describes colored biodegradable microparticle based compositions wherein the compositions comprise drug encapsulated microparticles and coloring agent encapsulated microparticles mixed in any proportion. Medical applications of the compositions and methods described in this invention are also described.

IPC Classes  ?

  • A61F 2/02 - Prostheses implantable into the body
  • A61K 9/50 - Microcapsules
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/727 - HeparinHeparan
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

16.

COMPOSITIONS, METHODS AND DEVICES FOR LOCAL DRUG DELIVERY

      
Application Number US2014026467
Publication Number 2014/160387
Status In Force
Filing Date 2014-03-13
Publication Date 2014-10-02
Owner PATHAK HOLDINGS, LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

This invention provide novel compositions, methods and devices for sustained drug delivery. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes. The injected compositions may undergo variety of physical chemical changes upon deposition. The physical and chemical changes enables improved drug encapsulation and sustained drug release. Also described are new methods to form polymer microparticles or polymer films/implants in situ inside the tissue. The invention also describes colored biodegradable microparticle based compositions wherein the compositions comprise drug encapsulated microparticles and coloring agent encapsulated microparticles mixed in any proportion. Medical applications of the compositions and methods described in this invention are also described.

IPC Classes  ?

  • A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests

17.

Methods for local drug delivery by microinjection

      
Application Number 14209827
Grant Number 09072678
Status In Force
Filing Date 2014-03-13
First Publication Date 2014-09-18
Grant Date 2015-07-07
Owner Pathak Holdings LLC (USA)
Inventor Pathak, Chandrashekhar P.

Abstract

This invention provide novel compositions, methods and devices for sustained drug delivery. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes. The injected compositions may undergo variety of physical chemical changes upon deposition. The physical and chemical changes enables improved drug encapsulation and sustained drug release. Also described are new methods to form polymer microparticles or polymer films/implants in situ inside the tissue. The invention also describes colored biodegradable microparticle based compositions wherein the compositions comprise drug encapsulated microparticles and coloring agent encapsulated microparticles mixed in any proportion. Medical applications of the compositions and methods described in this invention are also described.

IPC Classes  ?

  • A61F 2/02 - Prostheses implantable into the body
  • A61K 9/50 - Microcapsules
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/727 - HeparinHeparan
  • A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61M 5/30 - Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or cartridges

18.

METHODS AND COMPOSITIONS FOR FILLING FLESHY FRUITS AND VEGETABLES

      
Application Number US2010058205
Publication Number 2011/066505
Status In Force
Filing Date 2010-11-29
Publication Date 2011-06-03
Owner PATHAK HOLDINGS LLC (USA)
Inventor
  • Pathak, Chandrashekhar, P.
  • Pathak, Nivedita, C.

Abstract

Systems and methods for filling a fleshy fruit or vegetable with a filler are described. Embodiments include tool having an expandable member that is expandable to an expanded position to make a cavity in the fruit and collapsible to a collapsed position for withdrawal from the fruit, with the expandable member in the expanded state comprising a cross-section that is larger than the maximum diameter of the tool in the collapsed position. A cavity may be created without substantially affecting the natural visual appearance of the fruit or vegetable. Fillers and filling methods are disclosed.

IPC Classes  ?

  • A23L 1/212 - Preparation of fruits or vegetables (of pulse A23L 1/20; treating harvested fruit or vegetables in bulk A23N)
  • A23L 1/29 - Modifying nutritive qualities of foods; Dietetic products ( A23L 1/09 takes precedence;dietetic salt substitutes A23L 1/22)
  • A23P 1/08 - Coating of foodstuffs; Coatings therefor; Making of laminated, multilayered or stuffed foodstuffs

19.

Radio-opaque compounds, compositions containing same and methods of their synthesis and use

      
Application Number 10914701
Grant Number 07790141
Status In Force
Filing Date 2004-08-09
First Publication Date 2005-02-17
Grant Date 2010-09-07
Owner Pathak Holdings, LLC (USA)
Inventor
  • Pathak, Chandrashekhar P.
  • Thigle, Sanjay M.

Abstract

Radio-opaque biodegradable compositions are formed by modifying terminal groups of synthetic and natural biodegradable polymers such as polylactones with iodinated moieties. The biodegradable property of the compositions renders them suitable for use in medical field such as drug delivery, imaging. Compounds disclosed in this invention exist as neat liquid. Certain compositions disclosed in this invention form hydrophobic iodine rich domains when dissolved in water, such domains provide better contrasting properties as well as ability to dissolve hydrophobic bioactive drugs. Certain iodinated moieties disclosed in the invention are capable of cross linking natural proteins in situ in presence of suitable catalysts and co-catalysts.

IPC Classes  ?

  • A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61M 36/14 - Radioactive dressings